Haemostasis during early treatment of childhood acute lymphoblastic leukaemia with the ALLTogether protocol

Johannes Fermér¹, Jonas Jalnäs^{2

3}, Jonas Abrahamsson⁴, Magnus Borssen⁵, Isabella Donnér⁴, Ludvig Henriksson⁵, Mats Heyman^{2

3}, Anna Sällfors Holmqvist^{6

7}, Anders Valind^{7

8}, Hartmut Vogt^{9

10}, Anne Wretman^{9

10}, Otto Zhou¹, Arja Harila¹, Susanna Ranta^{2

3}

Affiliations

¹ Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
² Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
³ Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
⁴ Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
⁵ Department of Pediatrics, Umeå University Hospital, Umeå, Sweden.
⁶ Department of Clinical Sciences, Lund University, Lund, Sweden.
⁷ Childhood Cancer Center, Skåne University Hospital, Lund, Sweden.
⁸ Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
⁹ Crown Princess Victoria Children's Hospital, Linköping, Sweden.
¹⁰ Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

Johannes Fermér et al. Acta Paediatr. 2024 Dec.

. 2024 Dec;113(12):2676-2678.

doi: 10.1111/apa.17398. Epub 2024 Aug 27.

¹ Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
² Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
³ Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
⁴ Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
⁵ Department of Pediatrics, Umeå University Hospital, Umeå, Sweden.
⁶ Department of Clinical Sciences, Lund University, Lund, Sweden.
⁷ Childhood Cancer Center, Skåne University Hospital, Lund, Sweden.
⁸ Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
⁹ Crown Princess Victoria Children's Hospital, Linköping, Sweden.
¹⁰ Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

No abstract available

References

1. Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia: results of the PARKAA study. Thromb Haemost. 2003;90(8):235‐244.
1. Coelho MC, Santos CV, Vieira Neto L, Gadelha MR. Adverse effects of glucocorticoids: coagulopathy. Eur J Endocrinol. 2015;173(4):M11‐M21.
1. Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost. 1995;21(4):390‐401.
1. Alqasim AMZ, Al‐Hadithi RH, Al‐Khalidi AN. Coagulopathic side effect of L‐asparaginase on fibrinogen level in childhood acute lymphoblastic leukemia during induction phase. Hematol Oncol Stem Cell Ther. 2019;12(1):67‐69.
1. Appel IM, van Kessel‐Bakvis C, Stigter R, Pieters R. Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia. Leukemia. 2007;21(11):2377‐2380.